Public Sector Pension Investment Board Has $6.76 Million Stock Position in Enovis Corporation $ENOV

Public Sector Pension Investment Board boosted its stake in Enovis Corporation (NYSE:ENOV) by 14.5% in the third quarter, Holdings Channel reports. The firm owned 222,939 shares of the company’s stock after purchasing an additional 28,236 shares during the quarter. Public Sector Pension Investment Board’s holdings in Enovis were worth $6,764,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC lifted its holdings in shares of Enovis by 42.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after acquiring an additional 367 shares during the period. EverSource Wealth Advisors LLC boosted its holdings in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in shares of Enovis in the 2nd quarter valued at $46,000. SJS Investment Consulting Inc. raised its holdings in shares of Enovis by 30,340.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after buying an additional 1,517 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its position in shares of Enovis by 235.2% during the 3rd quarter. Nisa Investment Advisors LLC now owns 1,703 shares of the company’s stock worth $52,000 after buying an additional 1,195 shares during the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Enovis Price Performance

Enovis stock opened at $22.08 on Thursday. The stock’s 50 day moving average is $24.77 and its 200 day moving average is $28.39. Enovis Corporation has a one year low of $21.00 and a one year high of $44.76. The firm has a market cap of $1.26 billion, a P/E ratio of -0.93 and a beta of 1.52. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.22 and a quick ratio of 1.16.

Analyst Upgrades and Downgrades

ENOV has been the subject of a number of research reports. Evercore reissued an “outperform” rating on shares of Enovis in a report on Monday, January 12th. UBS Group reiterated a “buy” rating and set a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. Canaccord Genuity Group cut their target price on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a research report on Wednesday, December 17th. Wells Fargo & Company increased their price target on Enovis from $41.00 to $42.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Finally, BTIG Research started coverage on Enovis in a report on Tuesday, January 6th. They issued a “buy” rating and a $41.00 target price for the company. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $46.71.

Insider Activity

In other Enovis news, EVP Daniel A. Pryor sold 999 shares of the firm’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $27.20, for a total value of $27,172.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John Kleckner bought 2,468 shares of Enovis stock in a transaction dated Tuesday, November 25th. The stock was purchased at an average price of $30.32 per share, with a total value of $74,829.76. Following the completion of the purchase, the insider owned 12,302 shares in the company, valued at $372,996.64. This trade represents a 25.10% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 2.70% of the stock is owned by corporate insiders.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.